Caisse DE Depot ET Placement DU Quebec Has $58 Million Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Caisse DE Depot ET Placement DU Quebec boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 149.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 174,569 shares of the company's stock after purchasing an additional 104,705 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned about 0.56% of Medpace worth $57,997,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the stock. R Squared Ltd acquired a new position in Medpace during the 4th quarter worth $30,000. SBI Securities Co. Ltd. acquired a new stake in Medpace during the fourth quarter valued at approximately $31,000. Jones Financial Companies Lllp grew its position in shares of Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after acquiring an additional 110 shares in the last quarter. Lindbrook Capital LLC increased its holdings in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after acquiring an additional 29 shares during the last quarter. Finally, Assetmark Inc. raised its position in shares of Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after acquiring an additional 29 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Leerink Partnrs raised shares of Medpace to a "hold" rating in a research report on Monday, March 24th. Truist Financial cut their price objective on shares of Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a research note on Wednesday, April 23rd. Leerink Partners initiated coverage on shares of Medpace in a research note on Monday, March 24th. They set a "market perform" rating and a $330.00 target price on the stock. William Blair reiterated a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Finally, Robert W. Baird dropped their target price on Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a report on Wednesday, April 23rd. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Medpace presently has an average rating of "Hold" and a consensus price target of $349.30.

Medpace Price Performance

Shares of Medpace stock traded up $7.07 during trading on Wednesday, hitting $295.84. 122,735 shares of the company were exchanged, compared to its average volume of 434,167. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $459.77. The firm's fifty day moving average price is $308.38 and its 200 day moving average price is $329.37. The firm has a market capitalization of $8.50 billion, a P/E ratio of 23.40, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $3.06 by $0.61. The business had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period last year, the business earned $3.20 earnings per share. As a group, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the sale, the director now owns 2,998 shares of the company's stock, valued at $904,856.36. This trade represents a 36.35 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 20.30% of the company's stock.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.